rare disease pricing
1 statements across 1 episodes · 1 bullish · 0 bearish · 1 people on the record · first statement Jan 14, 2019 by Jean Hynes · across every show →
Everything said about rare disease pricing, oldest first
Jan 14, 2019 positive
Hynes: Biopharma must price rare diseases high and common diseases low
“I'm a big believer that this industry needs to price for the risk they take and the innovation they take, and they need to earn a return over the life cycle of their patents. And if you are going after a very large disease, such as cholesterol or heart failure…”